

Date: 02/11/20

Location: Virtual

Minutes: Draft

Committee members present:	
Anthony Wierzbicki (AW)	Present for notes 1 – 6
Sarah Ali (SAL)	Present for notes 1 – 5
Clare Allinson (CA)	Present for notes 1 – 5
Virginia Aylett (VA)	Present for notes 1 – 5
Tara Bashford (TB)	Present for notes 1 – 6
Neel Basudev (NB)	Present for notes 1 – 3
Roy Connell (RC)	Present for notes 1 – 5
Grainne Connolly (GC)	Present for notes 1 – 6
Jan Dudley (JD)	Present for notes 1 – 3
Hugh Gallagher (HG)	Present for notes 1 – 6
Deepa Kariyawasam (DK)	Present for notes 1 – 6
Arif Khwaja (AK)	Present for notes 1 – 6
Andrew Lewington (AL)	Present for notes 1 – 6
Fiona Loud (FL)	Present for notes 1 – 5
Catherine Pogson (CP)	Present for notes 1 – 6
Nicola Thomas (NT)	Present for notes 1 – 6

In attendance:		
Victoria Axe (VA)	Commissioning Manager	Present for notes 1 – 6
Steph Armstrong (SA)	Technical Analyst Health Economics	Present for notes 1 – 6
Chris Carmona (CC)	Senior Technical Analyst	Present for notes 1 – 6
Anne-Louise Clayton (AC)	Editor	Present for notes 1 – 6
Jackie Durkin (JD)	Administrator	Present for notes 1 – 6
Yolanda Martinez (YM)	Technical Analyst	Present for notes 1 – 6
Vonda Murray (VM)	Project Manager	Present for notes 1 – 6
Joshua Pink (JP)	Technical Adviser – Health Economics	Present for notes 1 – 6

Kidney Suite GComm 14 minutes

Philip Williams (PW)	Resource Impact Lead	Present for notes 1 – 6
Susan Spiers (SP)	Associate Director	Present for notes 1 – 6

Apologies:

Lucy Beggs	Technical Adviser (Health Economics)
Ivan Benett	Committee member
Rajib Pal	Committee member

1. Welcome and objectives for the meeting

The Chair welcomed the committee members and attendees to the 14th committee meeting on Kidney Injury & Disease. The Chair welcomed to the meeting; committee members, and NICE attendees.

The Chair informed the committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included:

- Reviewing new evidence, recommendation and research recommendation review for;
 - adults, children and young people with CKD, what constitutes a clinically significant decline in eGFR in terms of risk of kidney disease progression?
 - adults, children and young people with CKD what is the optimal monitoring frequency based on different rates of decline in eGFR?
 - adults, children and young people with suspected or diagnosed CKD, what is the effect of interventions to lower proteinuria?
 - adults, children and young people with CKD, what are the optimal blood pressure ranges for slowing kidney disease progression, and for reducing cardiovascular disease risk and mortality?
 - adults, children and young people, what is the accuracy of cystatin C-based equations to estimate GFR as a measurement of kidney function ?

The Chair asked all committee members to verbally declare any interests that have arisen since the last meeting. The Chair and senior members of the Developer team noted that FL would not be involved in discussing recommendations for suspected or diagnosed CKD (SGLT2 part of RQ2.3), what is the effect of interventions to lower proteinuria. The Chair and senior members of the Developer team noted that interests previously declared, did not prevent the attendees from fully participating in the meeting. New interests are noted below.

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Sarah Ali	Consultant in	Ramadan: implications	Direct,	Declare and

Kidney Suite GComm 14 minutes

Co-opted committee member	Diabetes and Endocrinology, Royal Free Foundation Trust London NHS	for patients with type 2 diabetes: talk for local GPs and Practice Nurses (Sponsored by Eli Lilly) Honorarium received	financial	participate
Sarah Ali Co-opted committee member	Consultant in Diabetes and Endocrinology, Royal Free London NHS Foundation Trust	Non-promotional educational meetings for GPs and primary care HCPs. Commissioned by GP Federation (CCG) and CLCH Trust. MERIT (Meeting Educational Requirements Improving Treatment). Meeting sponsored by Novo Nordisk. No personal financial benefit.	Direct, non-financial professional and personal	Declare and participate
Sarah Ali Co-opted committee member	Consultant in Diabetes and Endocrinology, Royal Free London NHS Foundation Trust	PI for MODIFY - Longitudinal assessment of multi-organ abnormality in patients with type 2 diabetes (Innovate UK and Perspectum Diagnostics Ltd)	Direct, non-financial professional and personal	Declare and participate
Sarah Ali Co-opted committee member	Consultant in Diabetes and Endocrinology, Royal Free London NHS Foundation Trust	Sub PI for FLOW - Effect of semaglutide versus placebo on the progression of renal impairment in subjects with type 2 diabetes and chronic kidney disease (Novo Nordisk)	Direct, non-financial professional and personal	Declare and participate
Sarah Ali Co-opted committee member	Consultant in Diabetes and Endocrinology, Royal Free London NHS Foundation Trust	Sub PI for SOUL Semaglutide cardiovascular outcomes trial in patients with type 2 diabetes (NovoNordisk)	Direct, non-financial professional and personal	Declare and participate
Sarah Ali Co-opted committee member	Consultant in Diabetes and Endocrinology, Royal Free London NHS Foundation Trust	Sub PI for StartRIGHT: A prospective study to assess utility of clinical features and biomarkers in classifying young adult diabetes (NIHR).	Direct, non-financial professional and personal	Declare and participate
Sarah Ali Co-opted	Consultant in Diabetes and Endocrinology,	Committee member of South Asian Health Foundation	Direct, non-financial professional	Declare and participate

Kidney Suite GComm 14 minutes

committee member	Royal Free London NHS Foundation Trust		and personal	
Sarah Ali Co-opted committee member	Consultant in Diabetes and Endocrinology, Royal Free London NHS Foundation Trust	Chair/ committee member of Muslim Council of Britain Diabetes Advisory Group	Direct, non-financial professional and personal	Declare and participate
Sarah Ali Co-opted committee member	Consultant in Diabetes and Endocrinology, Royal Free London NHS Foundation Trust	Committee member on the NICE diabetes update committee	Direct, non-financial professional and personal	Declare and participate
Sarah Ali Co-opted committee member	Consultant in Diabetes and Endocrinology, Royal Free London NHS Foundation Trust	Team lead for NHS England Project: Delivery of Diabetes Care in the Primary Care Network	Direct, non-financial professional and personal	Declare and participate
Sarah Ali Co-opted committee member	Consultant in Diabetes and Endocrinology, Royal Free London NHS Foundation Trust	Publication: COVID-19 in Black, Asian and Minority Ethnic populations: An evidence review and recommendations from the South Asian Health Foundation	Direct, non-financial professional and personal	Declare and participate
Sarah Ali Co-opted committee member	Consultant in Diabetes and Endocrinology, Royal Free London NHS Foundation Trust	Publication: COVID-19 and Ramadan '20: A Time for Reflection. BMJ Opinion online	Direct, non-financial professional and personal	Declare and participate
Sarah Ali Co-opted committee member	Consultant in Diabetes and Endocrinology, Royal Free London NHS Foundation Trust	Publication: Hanif S*, Ali SN*, Hassanein M, Khunti K, Hanif W. Managing People with Diabetes Fasting for Ramadan During the COVID-19 Pandemic: A South Asian Health Foundation Update. <i>Diabet Med.</i> 2020;37(7):1094-1102. doi:10.1111/dme.14312	Direct, non-financial professional and personal	Declare and participate

Kidney Suite GComm 14 minutes

Sarah Ali Co-opted committee member	Consultant in Diabetes and Endocrinology, Royal Free London NHS Foundation Trust	Publication: The South Asian Health Foundation UK Guidelines for Managing Diabetes during Ramadan: 2020 Update. Hanif W, Patel V, Ali SN, Karamat A, Saeed M, Hassanein M, Syed A, Chowdhury TA, Farooqi A, Khunti K.	Direct, non-financial professional and personal	Declare and participate
Sarah Ali Co-opted committee member	Consultant in Diabetes and Endocrinology, Royal Free London NHS Foundation Trust	Publication: Pharmacological management of South Asians with Type 2 Diabetes: Consensus Recommendations from the South Asian Health Foundation. Hanif W, Bellary S, Patel V, Farooqi A, Karamat MA, Saeed M, Ali S, Patel K, Khunti K	Direct, non-financial professional and personal	Declare and participate
Sarah Ali Co-opted committee member	Consultant in Diabetes and Endocrinology, Royal Free London NHS Foundation Trust	Presentation at the 4 th Annual Diabetes in Ramadan Conference (South Asian Health Foundation and Diabetes in Ramadan IDF Alliance): The South Asian Health Foundation (UK) Guidelines for Managing Diabetes during Ramadan: 2020 Update	Direct, non-financial professional and personal	Declare and participate
Sarah Ali Co-opted committee member	Consultant in Diabetes and Endocrinology, Royal Free London NHS Foundation Trust	Presentation at the 4 th Annual Diabetes in Ramadan Conference (South Asian Health Foundation and Diabetes in Ramadan IDF Alliance): Carb challenge workshop in Ramadan	Direct, non-financial professional and personal	Declare and participate
Sarah Ali Co-opted committee member	Consultant in Diabetes and Endocrinology, Royal Free London NHS Foundation Trust	Presentation at the 20 th Annual South Asian Health Foundation Conference: Pharmacological Management of Type 2 diabetes in South Asian	Direct, non-financial professional and personal	Declare and participate

Kidney Suite GComm 14 minutes

Sarah Ali Co-opted committee member	Consultant in Diabetes and Endocrinology, Royal Free London NHS Foundation Trust	Presentation at British Endocrine Society Annual Conference 2019: 'How do I manage..Which patients with gynaecomastia require more detailed investigation?'	Direct, non-financial professional and personal	Declare and participate
Tara Bashford	Lay member	Member of M3 global research project, post operative management and care. Concerning experience as a patient through dialysis and transplant.	Direct financial	Declare and participate
Hugh Gallagher Co-opted committee member	Consultant Nephrologist, Epsom and St. Helier NHS Trust	Co-author for a paper published in the BMJ; Quality improvement at scale: evaluation of the drivers and barriers to adoption and sustainability of an intervention to reduce late referral in chronic kidney disease	Direct, non-financial professional and personal	Declare and participate
Fiona Loud	Lay member	Member of AstraZeneca think tank, accelerate change together for chronic kidney disease. Payment given to Kidney Care UK	Indirect financial	Excluded from discussion and drafting of recommendations on suspected or diagnosed CKD, what is the effect of interventions to lower proteinuria.
Nicola Thomas	Professor of Kidney Care, School of health and Social care, London South Bank University	Appointed to Baxter Think Tank (staff education sub-group, assessing staff educational/training needs (medical and nursing) in the renal field across Europe, the Middle East and Africa), A provider of renal care products	Direct financial	Declare in participate
<p>2. RQ3.1 For adults, children and young people with CKD, what constitutes a clinically significant decline in eGFR in terms of risk of kidney disease progression?</p> <p>RQ3.2 For adults, children and young people with CKD what is the optimal</p>				

Kidney Suite GComm 14 minutes

monitoring frequency based on different rates of decline in eGFR?

- **Reruns**
- **Recommendation review**
- **Research recommendations**

The Chair introduced YM Technical Analyst, who presented the evidence for what constitutes a clinically significant decline in eGFR in terms of risk of kidney disease progression and what is the optimal monitoring frequency based on different rates of decline in eGFR, for adults, children and young people with CKD. The Chair thanked YM for her presentation. The Chair facilitated a discussion around the recommendations.

3. RQ2.3 For adults, children and young people with suspected or diagnosed CKD, what is the effect of interventions to lower proteinuria?

- **Reruns**
- **Recommendation review**
- **Research recommendations**

The Chair introduced YM Technical Analyst, who presented the evidence for adults, children and young people with suspected or diagnosed CKD, what is the effect of interventions to lower proteinuria. The Chair thanked YM for her presentation. The Chair facilitated a discussion around the recommendations.

4. RQ4.1 In adults, children and young people with CKD, what are the optimal blood pressure ranges for slowing kidney disease progression, and for reducing cardiovascular disease risk and mortality?

- **Reruns**
- **Recommendation review**
- **Research recommendations**

The Chair introduced YM Technical Analyst, who presented the evidence for what are the optimal blood pressure ranges for slowing kidney disease progression, and for reducing cardiovascular disease risk and mortality in adults, children and young people with CKD. The Chair thanked YM for her presentation. The Chair facilitated a discussion around the recommendations.

5. RQ1.1 What is the accuracy of cystatin C-based equations to estimate GFR as a measurement of kidney function in adults, children and young people?

- **Reruns**
- **Recommendation review**
- **Research recommendations**

The Chair introduced YM Technical Analyst, who presented the evidence for what is the accuracy of cystatin C-based equations to estimate GFR as a measurement of kidney function in adults, children and young people.

The Chair introduced SA Technical Analyst Health Economics who presented the

Kidney Suite GComm 14 minutes

health economic evidence for what is the accuracy of cystatin C-based equations to estimate GFR as a measurement of kidney function in adults, children and young people.

The Chair thanked YM and SA for their presentations. The Chair facilitated a discussion around the recommendations.

6. AOB

None

7. Summary and next steps

The Chair thanked the committee for their time and contribution to the meeting and reminded the committee of the date and time of the next committee meeting

Date of next meeting: 5/11/20 – 12:45 to 15:30

Location of next meeting: Virtual